Biofrontera Inc reports results for the quarter ended in June - Earnings Summary

• Biofrontera Inc BFRI reported a quarterly adjusted loss of 5 cents​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $-7.23. The mean expectation of two analysts for the quarter was for a loss of 77 cents per share. Wall Street expected results to range from $-1.19 to -35 cents per share.

• Revenue rose 34% to $7.84 million from a year ago; analysts expected $8.21 million.

• Biofrontera Inc's reported EPS for the quarter was a loss of 5 cents​.

• The company reported a quarterly loss of $257 thousand.

• Biofrontera Inc shares had risen by 26.9% this quarter and lost 58.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 27% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Biofrontera Inc is $11.50

This summary was machine generated from LSEG data August 16 at 04:53 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)